
Review Tool reports

UNDERSTANDING AND CONTEXTUALIZING THE REPORTS

Readers of these automated manuscript Review Tool reports are encouraged to use them to support them in performing their own assessment and 'health check' on a preprint prior to it completing peer review.

However, these should only be used as a guide, read within the overall context of the article itself, and should never replace full peer review. Please ensure you read the article fully alongside these and familiarize yourself with the tools and how they work, using the links provided below.

These reports are published under the terms of the [Creative Commons Attribution License](#)

SCISCORE® REPORTS: MDAR CHECKLIST FOR AUTHORS AND SCISCORE CORE REPORT

SciScore® (<https://sciscore.com>) scans the methodology section of an article for important scientific rigour criteria and key biological resources and highlights if these are accessible or have problems associated. The Materials, Design, Analysis, and Reporting (MDAR) report and Core report generated from this are included here for transparency and can be cited independently using the DOI below.

- Information on the MDAR report: <https://sciscore.com/reports/MDAR-Report.php>
- Information on the Core report: <https://sciscore.com/reports/Core-Report.php>

How to cite the SciScore reports for this article:

Malihy Z, Benaissa E, Ben Lahlou Y, Maleb A, Elouennass M. SciScore reports for: Osteoarticular tuberculosis of the ankle, a rare localization: a case report. *Access Microbiology*. 2023. <https://doi.org/10.1099/acmi.0.000654.v1.1>

ITHENTICATE® REPORT

iThenticate® (<https://www.ithenticate.com>) checks the submitted article against an extensive database of articles from the internet and scholarly publications and highlights where similar sentences or phrases have been used previously, including in the author's own published work. Each individual match is given a percentage score based on how much it overlaps with the previously existing work, and an overall similarity score is given. The report generated from this are included here for transparency and can be cited independently using the DOI below.

- FAQs: <https://www.ithenticate.com/products/faqs>
- Help pages: <https://help.turnitin.com/ithenticate/ithenticate-user/ithenticate-user.htm#TheSimilarityReport>

How to cite the iThenticate report for this article:

Malihy Z, Benaissa E, Ben Lahlou Y, Maleb A, Elouennass M. iThenticate report for: Osteoarticular tuberculosis of the ankle, a rare localization: a case report. *Access Microbiology*. 2023. <https://doi.org/10.1099/acmi.0.000654.v1.2>

Document Identifier: 2087_648770c4c3cd85.77968257

SciScore Report

Below you will find your SciScore report containing three tables. Your score is calculated based on adherence to scientific rigor criteria (Table 1) and identification of key biological resources (Table 2). Table 3 contains statistical tests and oligonucleotides but is not scored. If SciScore makes any mistakes, please [contact us](#) to help us learn and improve.

Table 1: Rigor Adherence Table

<u>Ethics</u>
Consent: Ethical approval Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy
<u>Inclusion and Exclusion Criteria</u>
not detected.
<u>Attrition</u>
not detected.
<u>Sex as a biological variable</u>
not detected.
<u>Subject Demographics</u>
Age: not detected.
Weight: not detected.
<u>Randomization</u>
not detected.
<u>Blinding</u>
not detected.
<u>Power Analysis</u>
not detected.
<u>Replication</u>
not required.

Table 2: Key Resources Table

Your Sentences	REAGENT or RESOURCE	SOURCE	IDENTIFIER
----------------	---------------------	--------	------------

SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. ***SciScore is not a substitute for expert review.*** SciScore also checks for the presence and correctness of several unique identifiers, including RRIDs (research resource identifiers) in the manuscript, detects sentences that appear to be missing RRIDs, and can even suggest RRIDs under certain circumstances. **All RRID suggestions should be verified;** only the author can know whether the suggestions are correct.

For a full description of scored criteria and tips for improving your score, please see <https://www.scicrunch.com/sciscorereport-faq>

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available	No antibodies detected. Please add identifiers for all resources where possible	
Cell Materials	Yes (indicate where provided: page no/section/legend)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No cell lines detected Please add identifiers for all resources where possible	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Not currently checked by SciScore	
Experimental Animals	Yes (indicate where provided: page no/section/legend)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No organisms detected Please add identifiers for all resources where possible	
Animal observed in or captured from the field: Provide species, sex and age where possible	Not currently checked by SciScore	
Model organisms: Provide Accession number in repository (where relevant) OR RRID	See laboratory animals section for information.	
Plants and microbes	Yes (indicate where provided: page no/section/legend)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Not currently checked by SciScore	
Microbes: provide species and strain, unique accession number if available, and source	Not currently checked by SciScore	
Human research participants	Yes (indicate where provided: page no/section/legend)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not detected.	
Provide statement confirming informed consent obtained from study participants.	Ethical approval Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy	
Report on age and sex for all study participants.	Age: not detected. Sex: not detected.	

Design

Study protocol	Yes (indicate where provided: page no/section/legend)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	Not detected.	
Laboratory protocol	Yes (indicate where provided: page no/section/legend)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Not detected.	
Experimental study design (statistics details)	Yes (indicate where provided: page no/section/legend)	n/a
State whether and how the following have been done, or if they were not carried out		
Sample size determination	not detected.	
Randomization	not detected.	
Blinding	not detected.	
inclusion/exclusion criteria	not detected.	
Sample definition and in-laboratory replication	Yes (indicate where provided: page no/section/legend)	n/a
State number of times the experiment was replicated in laboratory	Not detected.	
Define whether data describe technical or biological replicates	Not detected.	
Ethics	Yes (indicate where provided: page no/section/legend)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not detected.	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not detected.	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Not detected.	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: page no/section/legend)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Not currently checked by SciScore	

Analysis

Attrition	Yes (indicate where provided: page no/section/legend)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	not detected.	

Statistics	Yes (indicate where provided: page no/section/legend)	n/a
Describe statistical tests used and justify choice of tests.	Not detected.	

Data availability	Yes (indicate where provided: page no/section/legend)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Not detected.	
If data are publicly available, provide accession number in repository or DOI or URL.	Not detected.	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Not detected.	

Code availability	Yes (indicate where provided: page no/section/legend)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Not detected.	
If code is publicly available, provide accession number in repository, or DOI or URL.	Not detected.	

Analysis

Adherence to community standards	Yes (indicate where provided: page no/section/legend)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	Not currently checked by SciScore	

ACMI-S-23-00061.pdf

By Zakaria Malihy

WORD COUNT

1980

TIME SUBMITTED

12-JUN-2023 08:22PM

PAPER ID

100449197

CONFIDENTIAL

1 Osteoarticular tuberculosis of the ankle, a rare localization: a case 2 report 3

4 Malihy Z⁸, Benaissa E*, Belouad E* Benahlou Y*, Chadli M*, Maleb A**, Elouennass M*

5 ³
6 * Department of Bacteriology, Mohammed V Military Teaching Hospital/Faculty of Medicine and
7 Pharmacy (University Mohammed V), Rabat, Morocco.

8 ** Laboratory of Microbiology, Mohammed VI University Hospital/Faculty of Medicine and Pharmacy
9 (University Mohammed the first), Oujda, Morocco.

10

11 Corresponding author:

12 Malihy Z

13

14 Email addresses

15 Zakaria-malihy@um5.ac.ma; benaissaelmostafa2@gmail.com ; benahlouyassine@gmail.com ;
16 mariamachadli@gmail.com; maleb.adil@gmail.com ; elouennassm@yahoo.fr

17

18 Summary

19

20 Tuberculosis¹² is a real scourge, posing a real public health problem in countries where the disease is
21 endemic. Osteoarticular tuberculosis represents 2% to 5% of all tuberculosis cases and 11% to 15% of
22 extra-pulmonary tuberculosis cases. Involvement⁵ of the foot and ankle is rarer. We report the case of
23 osteoarticular tuberculosis of the ankle in a 71-year-old patient with type 2 diabetes and hypertension
24 who presented to the trauma department of the Mohammed V Military Hospital with a painful swelling
25 of the ankle. Standard X-rays and CT scan of the ankle showed inflammatory involvement of the bone
26 and joints. Antitubercular antibiotic therapy was instituted for nine months. Given the context of
27 endemicity, any atypical presentation of lingering bone lesions should raise the suspicion of
28 osteoarticular tuberculosis in order to ensure early therapeutic management.

29

30 **Keywords:** tuberculosis, ankle, PCR

31

32 Introduction

33

34 Tuberculosis⁴ is a major public health problem and is one of the top 10 causes of death worldwide.
35 According to the WHO, nearly 35 000 cases are reported each year in Morocco in 2021.

36

37 Osteoarticular tuberculosis accounts for 2% to 5% of all tuberculosis and 11% to 15% of
38 extrapulmonary tuberculosis [1,2]. Tuberculous spondylodiscitis is the most common (50% of cases)
39 [3,4]. Involvement of the foot and ankle is rarer [5].

40

41 We report a rare case⁹ of osteoarticular tuberculosis of the ankle in a 71-year-old diabetic and
42 hypertensive patient admitted for ankle arthritis and we emphasize the value of molecular biology in
43 the early management of these rare pathologies.

44

45 Observation


46

47 A 71-year-old patient with type 2 diabetes, hypertension⁵, and right hemiparesis following an ischemic
48 stroke, without any history of tuberculosis exposure, was admitted for a right ankle swelling over 01
49 month without any history of trauma. The clinical examination found a warm, red, fluctuating, and

50 painful swelling of the ankle. Joint mobilization was painful. The patient did not present any signs of
51 tuberculosis infection. Soft tissue ultrasound showed a poorly defined hypoechoic, heterogeneous
52 swelling extending into the joint with infiltration of the muscular and tendinous structures suggesting
53 a complicated abscessed tenosynovitis and myositis.

54

55 The ankle CT scan revealed a diffuse heterogeneous appearance of the bone structure with lytic
56 lesions of the subchondral bone and bone cortex accompanied by diffuse infiltration of soft tissues and
57 muscle calcifications (Figure 1).



58

59

Figure 1 :Lytic lesions of the subchondral bone and cortical bone with diffuse infiltration of soft tissue.

60

61

62 The thoracic CT scan allowed the visualization of diffuse bronchial micronodular lesions, which
63 converge in places with a bilateral pleural effusion, more marked on the right (figure 2).

64



65

66

67

68

69 On a biological level, the laboratory results showed a CRP of 138.7 mg/L, lymphopenia (0.5 G/L), and
70 normochromic microcytic anemia of 9.5 g/dL. The peripheral smear was normal with no atypical cells.
71 The renal and hepatic function were preserved and no electrolyte abnormalities were reported.

72

73 During the surgical operation, the pus was collected for cytbacteriological analysis. The sample was
74 seeded on Columbia agar with 5% sheep blood, Polyvitex® chocolate agar, and in a Heart-Brain broth
75 for enrichment which was then sub-cultured on blood agar. Incubation was performed aerobically at
76 37°C for 18-24 hours. All cultures and subcultures were found sterile. The direct examination of the
77 deep pus stained by Gram's method showed a significant inflammatory cellular reaction mainly
78 composed of polynuclear cells with no bacterial flora detected.

79

Figure 2: Diffuse bronchial micronodules.

80 The mycobacteriological examination of the pus was carried out and showed Acid-Fast Bacilli (AFB) on
81 direct examination (Figure 3) after Ziehl-Neelsen staining (1 to 10 AFB/100 fields). The culture in solid
82 Löwenstein Jensen medium and liquid MGIT (Mycobacterium Growth Indicator Tube) medium became
83 positive on days 21 and 10, respectively. Real-time PCR (GeneXpert MTB/RIF®, Cepheid) allowed the
84 detection of the *Mycobacterium tuberculosis* complex at a very low level without detection of
85 resistance to rifampicin.
86



87

88

89

90

Figure 3: Acid-fast bacillus found on direct examination by Ziehl-Neelsen staining.

91 In accordance with the Moroccan national anti-tuberculosis program, a nine-month course of anti-
92 bacillary antibiotic therapy was used to treat the patient: the combination of ethambutol,
93 pyrazinamide, isoniazid, and rifampicin for two months followed by the combination of isoniazid and
94 rifampicin for the remaining seven months. The treatment was successful, with good clinical tolerance,
95 disappearance of symptoms and no relapse 5 months after completion of treatment.
96

97 Discussion

98

99 Osteoarticular tuberculosis represents 2% to 5% of all tuberculosis cases and 11% to 15% of
100 extrapulmonary tuberculosis cases [1,2]. Tuberculosis spondylodiscitis is the most frequent (50% of
101 cases) [3,4]. Involvement of the foot and ankle is rarer [5]. Tuberculous osteoarthritis usually results
102 from hematogenous dissemination from an initial pulmonary, lymph nodes or other organ infection,
103 which may be symptomatic or unnoticed [8]. Osteoarticular tuberculosis most often occurs in an
104 immunocompromised individual (HIV infection, corticosteroid therapy, immunosuppressive
105 treatment, diabetes, chronic renal failure) with a bimodal age distribution: 55 years in native
106 populations and 20- 35 years in immigrants [10].
107

108 The atypical location, the insidious clinical presentation, the lack of an initial diagnosis of pulmonary
109 tuberculosis, as well as the hemiparesis, explains the delayed diagnosis. The presence of tuberculosis
110 impregnation signs such as night sweats and general deterioration are rare, and the main clinical signs
111 are pain, swelling and functional impotence [6].
112

113 The chest X-ray lacks specificity because more than 80% of patients do not have concomitant active
114 tuberculosis. [7].
115

116 The standard ankle radiography, thoracic CT and ankle CT are nonspecific but allow for the detection
117 of lesions and help determine their nature. MRI is the preferred examination because it ensures early

118 detection, from the beginning of the infection, of the affected bone parts and their extension to the
119 soft tissues and neighboring joints. [6].

120

121 The anatomopathological study, although specific, was not performed given the purulent nature of the
122 sample.

123123

124 The laboratory tests allowed us to detect the presence of an inflammatory syndrome. The high CRP
125 and the significant cellular reaction in the pus, associated with sterile cultures, led to the search for
126 Koch's Bacillus by molecular method and direct examination with culture. In extrapulmonary
127 tuberculosis, samples are often paucibacillary, hence the interest in molecular methods that have a
128 high sensitivity and specificity (92-98%) for the diagnosis of *Mycobacterium tuberculosis* complex, with
129 a short turnaround time for results (2 hours) and a good positive predictive value for rifampin
130 resistance (98%) [9]. Direct examination and culture are still necessary. Indeed, culture on solid media
131 allows obtaining strains for further study, especially for exploring resistance to anti-tuberculosis drugs
132 in case of therapeutic failure. Culture in liquid media makes up for the slow growth in solid media.
133 Direct examination, when positive, confirms the presence of Mycobacterium spp. by observing the
134 acid-fast bacilli.

135

136 Treatment relies on anti-bacillary drugs, which slow down the progression toward sequelae, namely
137 chronic pain, and deformity. [6] The majority of lesions heal within 6-12 weeks under medical
138 treatment. [8]

139

140 Surgical treatment is indicated in case of failure of medical treatment when synovitis, fistula, or abscess
141 persist [6]. Since the introduction of anti-tuberculosis quadri-chemotherapy, the indications for
142 surgery have become very restricted and selective, and are limited to the prevention or correction of
143 deformities as well as the improvement of the function of the affected joint [8]. Arthrodesis
144 procedures are mainly indicated at the level of the foot and ankle. [6]

145

146 Conclusion

147

148 Given the endemic context, any atypical presentation of lingering bone lesions should raise the
149 suspicion of osteoarticular tuberculosis to ensure early therapeutic management. The treatment of
150 osteoarticular tuberculosis is multidisciplinary and requires coordination between the physician,
151 bacteriologist, and surgeon.

152

153 Ethical approval

154 Written informed consent was obtained from the patient to publish this report in accordance with
155 the journal's patient consent policy.

156

157 Author contributions

158 ZM contributed to the initial drafting of the manuscript, while BE, BY, MA, and CM revised it. ELM
159 provided the final approval for the version that will be published.

160

161 Funding information

162 This work received no specific grant from any funding agency.

163

164 Competing interests

165 The authors declare no competing interest.

166

167 References

168

169 1. Evanchick CC, Davis DE, Harrington TM. Tuberculosis of peripheral joints: an often missed

- 170 diagnosis. *J Rheumatol.* 1986 Feb;13(1):187–9.
171
- 172 2. Jutte PC, van Loenhout-Rooyackers JH, Borgdorff MW, van Horn JR. Increase of bone and joint
173 tuberculosis in The Netherlands. *J Bone Joint Surg Br.* 2004 Aug;86(6):901–4.
174
- 175 3. Pertuiset E, Beaudreuil J, Horowitzky A, Lioté F, et al. Epidemiological aspects of osteoarticular
176 tuberculosis in adults. Retrospective study of 206 cases diagnosed in the Paris area from 1980 to
177 1994. *Presse Med.* 1997 Mar 8 ;26(7) :311–5.
178
- 179 4. Benbouazza K, El Maghraoui A, Lazrak N, Bezza A, Allali F, Hassouni F, et al. Les aspects
180 diagnostiques de la tuberculose ostéoarticulaire - Analyse d'une série de 120 cas identifiés dans un
181 service de rhumatologie. *Sem Hop Paris.* 1999; 75:1057–64.
182
- 183 5. Tuli SM. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 1991. Tuberculosis of the skeletal
184 system (bones, joints, spine and bursal sheaths) pp. 3–122.
185
- 186 6. Hachimi H, Tahiri L, Kadi N, Ibrahim A, Elmriani A, Harzy T. Tuberculose du médio-pied, une
187 localisation inhabituelle : à propos d'un cas. *Pan Afr Med J.* 2012; 11:53. French. Epub 2012 Mar 21.
188 PMID: 22593789; PMCID: PMC3343681.
189
- 190 7. Yombi, J.-C. ; Vandercam, B. ; Cornu, O. ; Lecouvet, F. ; Leemrijse, T. (2007). Ostéoarthrite
191 tarsienne : une localisation rare de la tuberculose. *Revue de Chirurgie Orthopédique et Réparatrice*
192 *de l'Appareil Moteur*, 93(7), 740–745. doi :10.1016/S0035-1040(07)73261-0
193
- 194 8. Tuli, S. M. (2002). *General Principles of Osteoarticular Tuberculosis. Clinical Orthopaedics and*
195 *Related Research*, 398(), 11–19. doi:10.1097/00003086-200205000-00003
196
- 197 9. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for
198 pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev.* 2014 Jan
199 21;2014(1):CD009593. doi: 10.1002/14651858.CD009593.pub3.
200
- 201 10. Puppo, L., D., Janssens, J., Kherad, O., Younossian, A., B., Frésard, I. (2016), Tuberculose osseuse :
202 quand faut-il y penser ? *Rev Med Suisse*, 2, no. 504, 262–265.

16%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.ncbi.nlm.nih.gov Internet	41 words — 3%
2	S. Oucharqui, H. Adil, E. Benaissa, F. Bssaibis, I. En-nafaa, A. Maleb, J. El fenni, M. Elouennass. "Breast tuberculosis: A forgotten diagnosis", IDCases, 2021 Crossref	38 words — 2%
3	doaj.org Internet	36 words — 2%
4	www.researchgate.net Internet	23 words — 1%
5	cyberleninka.org Internet	20 words — 1%
6	journals.lww.com Internet	18 words — 1%
7	Elmostafa Benaissa, Mohamed Habib Bahalou, Yassine Safi, Fatna Bssaibis et al. "Primary tuberculosis of the parotid gland: A forgotten diagnosis about a case!", Clinical Case Reports, 2021 Crossref	11 words — 1%
8	Ionela-Larisa Miftode, Maria-Antoanela Pasare, Radu-Stefan Miftode, Eduard Nastase et al. "What Doesn't	11 words — 1%

Kill Them Makes Them Stronger: The Impact of the Resistance Patterns of Urinary Enterobacterales Isolates in Patients from a Tertiary Hospital in Eastern Europe", Antibiotics, 2022

Crossref

9 www.recentmedicalfindings.com 11 words — 1%

Internet

10 www.researchsquare.com 11 words — 1%

Internet

11 Derek Armstrong, Stefanie Fisher, Marissa Totten, Nicole Parrish. "An Analytic Feasibility Study of the BD MAX™ MDR-TB Assay for Testing of Non-Sputum Specimens for Detection of the Mycobacterium tuberculosis Complex (MTBC) and Isoniazid (INH) and Rifampin (RIF) Resistance", Diagnostic Microbiology and Infectious Disease, 2023

Crossref

12 file.scirp.org 9 words — 1%

Internet

13 Ali, Nadeem, Abedullah Bhat, Khalid Muzzafar, and Akeela Fatima. "Isolated cystic tuberculosis of medial cuneiform: a case report", International Journal of Research in Medical Sciences, 2013.

Crossref

14 Kai Ling Chin, Maria E. Sarmiento, Nadine Alvarez-Cabrera, Mohd Nor Norazmi, Armando Acosta. "Pulmonary non-tuberculous mycobacterial infections: current state and future management", European Journal of Clinical Microbiology & Infectious Diseases, 2019

Crossref

EXCLUDE QUOTES OFF

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES OFF

EXCLUDE MATCHES OFF